Nope, but cheap IP is for other Pharma companies. Be mindful of other companies making progression in the space and the possibility that someone picks this up in a fire sale for an easy route to a well patented approach to reliable potency assays in MSc delivery - a hurdle for some companies with regulators in the space.
$7 million mkt cap would be less than the stationary expenses of some of the larger Pharmas'.
- Forums
- ASX - By Stock
- CMB
- Ann: Notice of Termination of Kyocera Licence
Ann: Notice of Termination of Kyocera Licence, page-15
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CMB (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.772M |
Open | High | Low | Value | Volume |
40.0¢ | 40.0¢ | 40.0¢ | $210 | 525 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 1971 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 0.350 |
1 | 342 | 0.205 |
1 | 2500 | 0.200 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 1971 | 2 |
0.420 | 1910 | 1 |
0.500 | 51 | 1 |
0.545 | 13403 | 1 |
0.600 | 2000 | 1 |
Last trade - 10.02am 08/08/2024 (20 minute delay) ? |
Featured News
CMB (ASX) Chart |